Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens

View/ Open
Issue Date
2019-02-15Author
Whitaker, Neal
Hickey, John M.
Kaur, Kawaljit
Xiong, Jian
Sawant, Nishant
Cupo, Albert
Lee, Wen-Hsin
Ozorowski, Gabriel
Medina-Ramírez, Max
Ward, Andrew B.
Sanders, Rogier W.
Moore, John P.
Joshi, Sangeeta B.
Volkin, David B.
Dey, Antu K.
Publisher
Elsevier
Type
Article
Article Version
Scholarly/refereed, publisher version
Rights
© 2019 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association®.
Metadata
Show full item recordAbstract
The induction of broadly neutralizing antibodies (bNAbs) is a major goal in the development of an effective vaccine against HIV-1. A soluble, trimeric, germline (gI) bNAb-targeting variant of the HIV-1 envelope glycoprotein (termed BG505 SOSIP.v4.1-GT1.1 gp140, abbreviated to GT1.1) has recently been developed. Here, we have compared this new immunogen with the parental trimer from which it was derived, BG505 SOSIP.664 gp140. We used a comprehensive suite of biochemical and biophysical methods to determine physicochemical similarities and differences between the 2 trimers, and thereby assessed whether additional formulation development efforts were needed for the GT1.1 vaccine candidate. The overall higher order structure and oligomeric states of the 2 vaccine antigens were quite similar, as were their thermal, chemical, and colloidal stability profiles, as evaluated during accelerated stability studies. Overall, we conclude that the primary sequence changes made to create the gl bNAb-targeting GT1.1 trimer did not detrimentally affect its physicochemical properties or stability profiles from a pharmaceutical perspective. This developability assessment of the BG505 GT1.1 vaccine antigen supports using the formulation and storage conditions previously identified for the parental SOSIP.664 trimer and enables the development of GT1.1 for phase I clinical studies.
Description
This work is licensed under a Creative Commons Attribution 4.0 International License.
Collections
Citation
Whitaker, N., Hickey, J. M., Kaur, K., Xiong, J., Sawant, N., Cupo, A., Lee, W. H., Ozorowski, G., Medina-Ramírez, M., Ward, A. B., Sanders, R. W., Moore, J. P., Joshi, S. B., Volkin, D. B., & Dey, A. K. (2019). Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. Journal of pharmaceutical sciences, 108(7), 2264–2277. https://doi.org/10.1016/j.xphs.2019.01.033
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.